Determining the Neurocognitive Status and the Functional Ability of Patients to Screen for HIV-Associated Neurocognitive Disorder (HAND)

Ritika Agarwal, Ravinder Singh Aujla, Amit Gupta, Mukesh Kumar

Department of Medicine, Chandra Laxmi Hospital, Vaishali Ghaziabad, UP, India

ABSTRACT

Background and Purpose: To adequately evaluate the extent of neurocognitive impairment in patient living with human immunodeficiency virus (PLHIV), a battery of neuropsychological tests is typically administered which are neither cost effective nor time efficient in the outpatient clinical setting. The aim of the study was to assess neurocognitive status and functional ability of people living with HIV and find a brief screening tool to identify those who would benefit from a full diagnostic evaluation.

Methods: The study enrolled 160 PLHIV (80 pre-antiretroviral therapy [ART] and 80 on ART) fulfilling the inclusion and exclusion criteria. Neurocognitive assessment and an assessment of Functional ability was done by using the Montreal Cognitive Assessment (MoCA) and Lawton and Brody Instrumental Activities of Daily Living Scale scale, respectively.

Results: The study population consisted of 75.6% males and 24.4% females with mean age of 44±10 years. The overall prevalence of HIV associated neurocognitive disorder (HAND) in the study subjects was 52.5%. Of these, 47.5% had asymptomatic neurocognitive impairment and 5% had minor neurocognitive disorder. In MoCA, the most frequently affected domains were Language (97.6%), visuospatial ability (92.9%) and memory (71.4%).

Conclusions: The prevalence of HAND in both groups were similar suggesting that neurocognitive impairment starts early in HIV infection. Memory and Visuospatial function impairment had the most predictive potential for detecting the presence of HAND. HAND screening is recommended in all PLHIV at enrolment into care. Simple tools like MoCA can be used in busy outpatient settings by healthcare workers to screen for HAND.

Keywords: HIV; Neurocognitive Disorder; Neurocognitive Assessment; Dementia: HAND

INTRODUCTION

Neurologic disorders are among the most frequent and devastating complications of human immunodeficiency virus (HIV) infection. Frequently, neurologic disorders negatively impact patient’s quality of life and their adherence to medical treatment leading to an increased chance of morbidity and mortality. These neurologic complications are either due to the primary pathogenic process of HIV infection or secondary to opportunistic infections.
In 2007, the National Institute of Mental Health and National Institute of Neurological Diseases and Stroke, United States\(^2\) suggested the term HIV associated neurocognitive disorder (HAND), which encompasses the entire spectrum of neurological disorders associated with HIV-1 infection. This classification proposed for HIV-related central nervous systems (CNS) impairment was referred to as the Frascati criteria\(^3\) that included milder forms of neurocognitive disturbance: asymptomatic neurocognitive impairment (ANI) and minor neurocognitive disorder (MND) and HIV associated dementia (HAD). ANI includes cognitive impairment involving at least 2 cognitive domains (performance of at least 1 standard deviation [SD] below the mean for norms on neuropsychological tests) and the cognitive impairment does not interfere with everyday functioning. MND includes cognitive impairment involving at least 2 cognitive domains (performance of at least 1 SD below the mean for norms on neuropsychological tests) and the cognitive impairment that produces at least mild interference in daily functioning. HAD includes marked cognitive impairment involving at least 2 cognitive domains (performance of at least 2 SD below the mean for norms on neuropsychological tests) and the cognitive impairment produces marked interference with day to day functioning.

To adequately evaluate the extent of neurocognitive impairment, a battery of neuropsychological tests is typically administered.\(^4\) However, these neuropsychological tests are neither cost effective nor time efficient in the outpatient clinical setting as they often require several hours to complete and can be labor intensive requiring additional trained personnel to administer and correctly score.\(^4\) One strategy to overcome this problem is to administer a brief screening tool to identify those who would benefit from a full diagnostic evaluation.

Montreal Cognitive Assessment (MoCA)\(^5\) is a screening tool that taps both cortical and subcortical processes which can be completed in about 10 minutes. This screening tool assesses 8 cognitive domains (attention and concentration, executive functions, memory, language, visuoconstructual skills, conceptual thinking, calculations, and orientation), which are scored within a range of G-30 points (higher scores reflecting better cognitive function). Valcour et al.\(^4\) recommended MoCA in combination with screening for depression (e.g., BDS-II) for screening of HAND. Easy accessibility on the internet and availability in different languages make it more attractive as a screening tool.

Hasbun et al.\(^5\) reported that only a MoCA score <26 was associated with neurocognitive impairment and had good screening accuracy (sensitivity: 85%, specificity:40% with a negative predictive value 48% and positive predictive value 81%). The MoCA provides some coverage of executive function, motor skill, language fluency and verbal learning. Therefore, the addition of a neurological examination focused on motor speed, tone, reflexes and integration with clinical variables (e.g., CD4 nadir, viral load) may add to the specificity.

The Mind Exchange Working Group\(^6\) advocates that all patient living with human immunodeficiency virus (PLHIV) should be screened for HAND regardless of symptoms or risk factors by using sensitive screening tools. This group recommended that patients should be screened early in the disease and then every 6–24 months. The British HIV Association also suggested annual screening of PLHIV, but they do not give details of which methods should be used and targeted populations.\(^7\) Guidelines from the European AIDS Clinical Society recommended that formal neuropsychological tests should be restricted to patients who have symptoms of impaired cognitive function based on a questionnaire.\(^8\)

Limited studies have been performed among PLHIV in India, mostly utilizing the earlier screening methods. There are no published reports on assessment of risk factors associated

https://dnd.or.kr

https://doi.org/10.12779/dnd.2020.19.1.119
with HAND among Indian subjects. This study aims to evaluate the prevalence of HAND and assess the associated risk factors in HIV infected individuals (both pre-antiretroviral therapy [ART] and on ART).

**METHODS**

A descriptive cross-sectional study was conducted in the Department of Medicine at Chandra Laxmi Hospital, Vaishali, Ghaziabad. Sample size was estimated using an expected prevalence of 50% for HIV associated neurocognitive disorder (HAND) in PLHIV. Hence the study enrolled 160 PLHIV who met the criteria were enrolled age ≥18 years, willing to give informed consent. For pre-ART-subjects — HIV positive, ART naïve, on ART subjects — HIV positive on ART for at least 3 months duration. Exclusion criteria included Known history of confounding neurological disorders, history of ongoing opportunistic infections of brain Toxoplasmosis, cryptococcal meningitis, history of head injury/seizures/loss of consciousness (>30 minutes) in the past, history of known psychiatric illness and active substance abuse.

All of the patients enrolled in the study underwent detailed history and clinical examination. Anthropometric assessment, general physical examination and systemic examination were done to assess the baseline clinical status, any opportunistic infections and for World Health Organization (WHO) clinical staging. All patients were subjected to CD4 count evaluation. Neurocognitive assessment was done in all subjects by administering the MoCA scale. A score of less than 26 was considered abnormal. Assessment of functional ability was done in all subjects by using the Lawton and Brody Instrumental Activities of Daily Living Scale (IADL), which contains 8 domains: ability to use a telephone, shopping, food preparation, housekeeping, laundry, mode of transportation, responsibility for own medications and the ability to handle finances.

On the basis of MoCA and IADL scores, we classified HAND into: ANI-MoCA score <26 and no functional impairment, MND-MoCA score <26 and mild functional impairment, and HAD-MoCA score <26 and severe functional impairment.

An assessment for risk factors for HAND was done on: age, sex, education, employment, immunological status (CD4 count), WHO staging, body mass index, ART regimen, ART duration, duration of HIV infection.

As presence of depression was considered to be a possible determinant of HAND, depressive symptoms were measured by administering the Patient Health Questionnaire-9 on all participants. Any level of depression based on the questionnaire was considered significant.

All statistical analysis was performed by using SPSS software (version 21.0; SPSS Inc., Chicago, IL, USA). Chi-square test was used to find association between independent and dependent variable and \( p<0.05 \) was considered statistically significant.

**RESULTS**

One hundred sixty patients were enrolled in our study, 80 were on some form of ART while other 80 were ART naïve. Table 1 describes the demographic profile of our patients.
Out of 80 the subjects on ART, most (77.5%) were on first line ART regimen, while only 22.5% were on second line ART regimen. Twenty-six subjects (32.5%) were on tenofovir+lamivudine+efavirenz, 6 (7.5%) on zidovudine+lamivudine+efavirenz, and 30 (18.8%) on zidovudine+lamivudine+nevirapine regimen. The second line regimen was tenofovir+lamivudine+ritonavir boosted atazanavir. The mean duration of ART among the ART group was 4.1±3.3 years (range −10 months to 15.6 years).

Out of 160 patients, 84 (52.5%) had HAND. Majority of them 76 (47.5%) had the mildest form of HAND, i.e., ANI. Five percent (n=8) fell into the MND category. No patient was found to have HAD.

Out of the 160 subjects, 96.3% (n=77) of pre-ART and 93.75% (n=75) of ART subjects reported normal daily living activities (ADL). Overall, only 5% of patients were found to have mild impairment in ADL and no patient had severe impairment in daily activities. The most common affected domain was food preparation (n=4 and 50%); while impairment in transportation, self-medication impairment and handling finance were other domains affected. The subjects who reported impairment in food preparation were all male (n=4).

In order to determine the risk factors for HAND in our study population, $p$-value was calculated as shown in Table 2. It was found that age >40 and lower education could be attributed to increased chances of HAND.

### DISCUSSION

Our study showed that the overall prevalence of HAND was 52.5% in our study population. The reported prevalence of HAND among PLHIV in literature is variable ranging from 5.9% to 90.1% in different studies.\(^{11-20}\)

This wide variation in the reported prevalence of HAND is due to multiple reasons such as intrinsic differences in the population studied due to differences in ethnicity, race and composition of population and other factors such as duration of HIV infection, ART. Another crucial point of difference is the tool or instrument used to detect and diagnose HAND.
Table 2. Determinants of HAND in PLHIV

| Variable                                    | PLHIV with HAND (n=84) | PLHIV without HAND (n=76) | p-value |
|----------------------------------------------|------------------------|---------------------------|---------|
| **Age (yr)**                                |                        |                           |         |
| Mean±SD                                     | 41.00±10.12            | 37.80±10.89               | 0.001   |
| <40                                         | 30 (35.7)              | 57 (75.0)                 |         |
| >40                                         | 54 (64.3)              | 19 (25.0)                 |         |
| **Sex**                                     |                        |                           |         |
| Male                                         | 64 (76.2)              | 57 (75)                   | 0.861   |
| Female                                       | 20 (23.8)              | 19 (25)                   |         |
| **Employment status**                       |                        |                           |         |
| Employed                                     | 43 (51.2)              | 47 (61.8)                 | 0.175   |
| Unemployed                                   | 41 (48.8)              | 29 (38.2)                 |         |
| **Education (standard/high school)**         |                        |                           |         |
| Years (mean±SD)                             | 7.99±3.40              | 10.78±2.40                | <0.001  |
| ≤12                                         | 80 (94.0)              | 56 (73.7)                 |         |
| >12                                         | 4 (6.0)                | 20 (26.3)                 |         |
| **WHO clinical staging**                    |                        |                           |         |
| Stage 1                                      | 75 (89.3)              | 65 (85.5)                 | 0.123   |
| Stage 2                                      | 0                      | 0                         |         |
| Stage 3                                      | 4 (4.8)                | 3 (3.9)                   |         |
| Stage 4                                      | 5 (6.0)                | 8 (10.5)                  |         |
| **Current CD4 counts (cells/mm³)**           |                        |                           |         |
| Mean±SD                                     | 348.20±208.30          | 365.00±180.50             |         |
| ≤200                                        | 22 (26.2)              | 16 (21.1)                 |         |
| 201–500                                     | 41 (48.8)              | 43 (56.6)                 | 0.503   |
| >500                                        | 21 (23.3)              | 17 (22.3)                 |         |
| **Nadir CD4 counts (cells/mm³)**             |                        |                           |         |
| Mean±SD                                     | 252.45±133.10          | 255.41±115.00             |         |
| ≤100                                        | 15 (17.9)              | 11 (14.5)                 | 0.488   |
| 100–200                                     | 19 (22.6)              | 14 (18.4)                 |         |
| 201–300                                     | 22 (26.2)              | 25 (32.9)                 |         |
| >300                                        | 28 (33.3)              | 26 (34.2)                 |         |
| **BMI (kg/m²)**                             |                        |                           |         |
| Mean±SD                                     | 21.65±3.07             | 22.02±3.18                | 0.898   |
| <18.5                                       | 12 (14.3)              | 9 (11.8)                  |         |
| 18.5–24.9                                   | 62 (73.8)              | 58 (76.3)                 |         |
| >25                                         | 10 (11.9)              | 9 (11.8)                  |         |
| **Mean duration of HIV infection (yr)**      |                        |                           | 0.624   |
| No depression                                | 20 (23.8)              | 14 (18.4)                 | 0.405   |
| Any depression                               | 64 (76.2)              | 62 (81.6)                 |         |
| **Receiving ART**                            |                        |                           |         |
| No                                          | 42 (52.5)              | 38 (47.5)                 | 0.137   |
| Yes                                         | 42 (52.5)              | 38 (47.5)                 |         |
| **Duration of ART (yr)**                    |                        |                           |         |
| Mean±SD                                     | 4.17±3.07              | 4.11±3.30                 | 0.324   |
| <1                                          | 6 (14.3)               | 5 (12.2)                  |         |
| 1–2                                         | 4 (9.5)                | 11 (28.9)                 |         |
| 2–3                                         | 9 (21.4)               | 5 (13.2)                  |         |
| >3                                          | 23 (54.8)              | 17 (44.5)                 |         |
| **Efavirenz containing ART regimen**        |                        |                           | 0.358   |
| Efavirenz based                              | 24 (54.5)              | 20 (55.5)                 |         |
| Non efavirenz based                          | 20 (45.5)              | 16 (44.5)                 |         |
| **PI containing ART regimen**               |                        |                           | 0.728   |
| PI based                                     | 9 (20.5)               | 9 (25.0)                  |         |
| Non-PI based                                 | 35 (79.5)              | 27 (75.5)                 |         |

Values are presented as number (%).
HAND: human immunodeficiency virus associated neurocognitive disorder, PLHIV: patient living with human immunodeficiency virus, SD: standard deviation, WHO: World Health Organization, BMI: body mass index, HIV: human immunodeficiency virus, ART: antiretroviral therapy, PI: protease inhibitor.
In the Charter study the prevalence of HAND was 52% as assessed by detailed neurocognitive test battery.\textsuperscript{11} Yakasai et al.\textsuperscript{21} also explored the prevalence of HAND in Nigeria by using a MDNPT battery combined with measures of functional status by using PAOFI and Karnofsky performance scale and reported HAND prevalence of 40% in ART naive and 30% in on ART subjects.

In India, the prevalence of HAND was determined to be 33.65% by using Mini-Mental State Exam and 32.5% by using International HIV Dementia Scale.\textsuperscript{13,15} There are no published reports of HAND prevalence using the MoCA instrument from India.

Among PLHIV with HAND in our study, the prevalence of ANI was 47.5%, and of MND was 5%. HAD was not demonstrated among our study population. Though the overall prevalence of HAND is high, there has been a global trend towards a decreasing prevalence of the more severe form of HAND like HAD while the milder forms and asymptomatic neurocognitive dysfunction is on the rise.

The ART probably benefits the brain via multiple mechanisms, including immune recovery, reduced immune activation, and viral suppression- both systemically and in the CNS. This may explain a mitigation in the severity of HAND. However, persistent high prevalence of neurocognitive dysfunction among PLHIV in the ART era could be due to early invasion of CNS by the virus soon after infection, which later on leads to long term complication of HAND. Our findings are consistent with existing literature in this regard. Heaton et al.\textsuperscript{22} noticed that the prevalence of HAD declined from 20% to 7% in the ART era. In the Charter study, out of 52% of PLHIV with HAND, 32.7% had ANI, 11.7% had MND and only 2.4% had HAD.

Just like our study, Grant et al.\textsuperscript{22}, McCutchan et al.\textsuperscript{23}, Cross et al.\textsuperscript{24} in US, Troncoso et al.\textsuperscript{25} in Brazil and Choi et al.\textsuperscript{26} in Africa also reported that older age (>40 years) was significantly associated with HAND. In Asian studies, Chan et al.\textsuperscript{27} in Singapore, Ku et al.\textsuperscript{28} in south Korea, Wang et al.\textsuperscript{29} in China and Achappa et al.\textsuperscript{17} in India also demonstrated a similar finding.

Education is considered to be a proxy for cognitive reserve. It was found that educational qualification below graduate level was significantly associated with HAND, consistent with our data, Cross et al.\textsuperscript{24} in the US and Troncoso et al.\textsuperscript{25} in Brazil also observed the association of HAND with lower years of education.

Unlike the previous study in South Asian population, the prevalence of HAND was not associated with the severity of HIV infection.\textsuperscript{27} This suggests that milder disease of HIV infection, i.e., lesser immune suppression does not appear to be protected from the development of HAND. This also supports the view that HIV penetrates the brain early in the infection and stays there leading to long term sequelae like HAND.

It is possible our CD4 counts were not truly reflective of the lowest CD4 counts of the patients. Since our study was a cross sectional in design, possibly a onetime assessment of CD4 counts and its association with HAND was inconclusive. A study in Nigeria by Yakasai et al.\textsuperscript{21} also reported a similar result in which HAND was found in 40% of the pre-ART group and 30% of the ART group. This finding signified that HAND is common in the present ART era and also implied that ART does not apparently prevent the development nor successfully treat HAND among PLHIV. However, this finding does not mean that ART is not an effective treatment for HAND as half of the study subjects were already on ART.
In the pre-ART era, a progressive subcortical dementia with motor and cognitive slowing was prominent among PLHIV with HAND. This was reflected by an abnormal score of MoCA in visuospatial function, memory, abstraction (reasoning) and concentration (attention) domains. However, in the ART era and in more advanced stages of HAND, cortical involvement is more frequently observed. Clinical features like aphasia, agnosia and apraxia are more typical of cortical involvement. Involvement of cortical structures is suggested by impairment in orientation, naming, language and calculation domains of a screening tool.

In our study also, both cortical and subcortical regions were observed to be affected in HAND. Further analysis on abnormal scores in MoCA cognitive domains showed that among PLHIV with HAND, 88% developed abnormality in >3 domains as shown in Table 3. It is interesting to observe that in spite of being diagnosed as cognitively normal (on total MoCA score), 31.6% and 52.7% of PLHIV without HAND developed abnormality in 2 and 3 domains respectively. Therefore, our study results suggest that an assumption of having abnormality in >3 cognitive domains must be considered among PLHIV with HAND.

It was shown that subjects with HAND performed poorly in all the domains on neurocognitive assessment with MoCA compared to those without HAND except for the domain of orientation (Table 4). A univariate logistic regression analysis was performed for all domains of MoCA. It showed that memory (odds ratio [OR], 35.500; \( p < 0.001 \)), visuospatial function (OR, 22.28; \( p < 0.001 \)), language (OR, 9.258; \( p = 0.001 \)), calculation (OR, 7.808; \( p < 0.001 \)), naming (OR, 4.419; \( p = 0.001 \)) and abstraction (OR, 4.440; \( p = 0.044 \)) were significantly associated with the presence of HAND. This implied that impairment in memory and visuospatial functions on the MoCA had the most predictive power for the presence of HAND.

Depression is considered to be a potential confounder for the presence of HAND among PLHIV. In our study, no association between HAND and depression was found. Our study

### Table 3. The frequency of abnormal score in cognitive domain among the study population

| Abnormal scores in | PLHIV with HAND (n=84) | PLHIV without HAND (n=76) |
|--------------------|------------------------|---------------------------|
| 1 domain           | 0                      | 10 (13.2)                 |
| 2 domains          | 0                      | 24 (31.6)                 |
| 3 domains          | 12 (14.3)              | 40 (52.7)                 |
| 4 domains          | 41 (48.8)              | 2 (2.6)                   |
| ≥5 domains         | 33 (39.2)              | 0                         |

Values are presented as number (%).

HAND: human immunodeficiency virus associated neurocognitive disorder, PLHIV: patient living with human immunodeficiency virus.

### Table 4. Frequency of abnormal scores and logistic regression results showing predictive power of individual cognitive domains on MoCA testing for HAND

| MoCA domains | PLHIV with HAND (n=84) | PLHIV without HAND (n=76) | OR       | Regression coefficient | 95% CI          | \( p \)-value |
|--------------|------------------------|---------------------------|----------|------------------------|----------------|--------------|
| Visuospatial | 78 (92.9)              | 28 (36.8)                 | 22.28    | 3.104                  | 8.600–57.752  | <0.001       |
| Naming       | 26 (31.0)              | 7 (9.2)                   | 4.419    | 1.486                  | 1.788–10.919  | 0.001        |
| Attention    | 6 (7.1)                | 1 (1.3)                   | 5.769    | 1.753                  | 0.678–49.065  | 0.072        |
| Calculation  | 43 (51.2)              | 9 (11.8)                  | 7.808    | 2.055                  | 3.450–17.670  | <0.001       |
| Language     | 82 (97.6)              | 62 (81.6)                 | 9.258    | 2.225                  | 2.029–42.240  | 0.001        |
| Abstraction  | 9 (10.7)               | 2 (2.6)                   | 4.440    | 1.495                  | 0.928–21.240  | 0.044        |
| Memory       | 60 (71.4)              | 5 (6.6)                   | 35.500   | 3.570                  | 12.763–98.742 | <0.001       |
| Orientation  | 2 (2.4)                | 0 (0)                     | 1.927    | 21.127                 | 1.658–2.239   | 0.176        |

Values are presented as number (%).

MoCA: Montreal Cognitive Assessment, HAND: HIV associated neurocognitive disorder, PLHIV: patient living with human immunodeficiency virus, OR: odds ratio, CI: confidence interval.

https://doi.org/10.12779/dnd.2020.19.1.19
findings are similar to the findings of Chan et al., who also did not find a significant association between HAND and depression.

Even a milder form of HAND could still hamper the quality of life of HIV infected patients. Since our study design is a one-time observational study, we cannot comment upon the impact of HAND on treatment adherence, morbidity, progression of existing cognitive dysfunction and mortality among PLHIV with HAND.

The present study had several limitations. As majority of the study subjects were enrolled from the outpatient setting, there was a chance of missing a patient with severe cognitive impairment and severe impairment in ADL. Another limitation is exclusion of subjects with substance abuse and CNS opportunistic infections which were found associated with HAND. Some of the risk factors observed in other studies like serum viral load and CSF viral load were not performed in this study due to non-availability of the test in our setup.

REFERENCES

1. Fauci AS, Lane HC. Human immunodeficiency virus disease: AIDS and related disorders. In: Longo DL, Kasper MD, Jameson JL, Fauci AS, Hauser SL, Loscalzo J, editors. *Harrison’s Principles of Internal Medicine*. 18th ed. New York: McGraw-Hill Companies; 2011;1506-1587.

2. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Chernera M, et al. Updated research nosology for HIV-associated neurocognitive disorders. *Neurology* 2007;69:1789-1799.

3. Gisslén M, Price RW, Nilsson S. The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? *BMC Infect Dis* 2011;11:356.

4. Valcour V, Paul R, Chiao S, Wendelken LA, Miller B. Screening for cognitive impairment in human immunodeficiency virus. *Clin Infect Dis* 2011;53:836-842.

5. Hasbun R, Eraso J, Ramireddy S, Wainwright DA, Salazar L, Grimes R, et al. Screening for neurocognitive impairment in HIV individuals: the utility of the montreal cognitive assessment test. *J AIDS Clin Res* 2012;3:186.

6. Mind Exchange Working Group. Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. *Clin Infect Dis* 2013;56:1004-1017.

7. British HIV Association. British HIV Association standards of care for people living with HIV 2018. Hertfordshire: British HIV Association; [cited 2019 Dec 23]. Available from: https://www.bhiva.org/standards-of-care-2018.

8. European AIDS Clinical Society. EACS guidelines [Internet]. Brussels: European AIDS Clinical Society; 2019 [cited 2019 Dec 23]. Available from: https://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html.

9. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. *Gerontologist* 1969;9:179-186.

10. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med* 2001;16:606-613.

11. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. *Neurology* 2010;75:2087-2096.

12. Deshpande AK, Patnaik MM. Nonopportunistic neurologic manifestations of the human immunodeficiency virus: an Indian study. *J Int AIDS Soc* 2005;7:2-4.
13. Singh R, Kaur M, Arora D. Neurological complications in late-stage hospitalized patients with HIV disease. Ann Indian Acad Neurol 2011;14:172-177.

14. Teja VD, Talasila SR, Venu L. Neurologic manifestations of HIV infection: an Indian hospital-based study. AIDS Read 2005;15:139-143.

15. Saini S, Barar KV. Assessment of neurocognitive functions in HIV/AIDS patients on HAART using the international HIV dementia scale. Int J Nutr Pharmacol Neurol Dis 2014;4:252-255.

16. Muniyandi K, Venkatesan J, Arutselvi T, Jayaseelan V. Study to assess the prevalence, nature and extent of cognitive impairment in people living with AIDS. Indian J Psychiatry 2012;54:149-153.

17. Achappa B, Priyadarshini S, Madi D, Bhaskaran U, Ramapuram JT, Rao S, et al. Neurocognitive dysfunction among HIV positive patients using International HIV dementia scale. Asian J Med Sci 2014;5:61-64.

18. Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010;24:1243-1250.

19. Vivithanaporn P, Heo G, Gamble J, Krentz HB, Hoke A, Gill MJ, et al. Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study. Neurology 2010;75:1150-1158.

20. McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol 2010;67:699-714.

21. Yakasai AM, Gudaji MI, Muhammad H, Ibrahim A, Owolabi LF, Ibrahim DA, et al. Prevalence and correlates of HIV-associated neurocognitive disorders (HAND) in Northwestern Nigeria. Neurol Res Int 2015;2015:122-129.

22. Grant I, Franklin DR Jr, Deutsch R, Woods SP, Vaida F, Ellis RJ, et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology 2014;82:2055-2062.

23. McCutchan JA, Marquie-Beck JA, Fitzsimons CA, Letendre SL, Ellis RJ, Heaton RK, et al. Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology 2012;78:485-492.

24. Cross S, Önen N, Gase A, Overton ET, Ances BM. Identifying risk factors for HIV-associated neurocognitive disorders using the international HIV dementia scale. J Neuroimmune Pharmacol 2013;8:1114-1122.

25. Troncoso FT, Conterno LO. Prevalence of neurocognitive disorders and depression in a Brazilian HIV population. Rev Soc Bras Med Trop 2015;48:390-398.

26. Choi Y, Townend J, Vincent T, Zaidi I, Sarge-Njie R, Jaye A, et al. Neurologic manifestations of human immunodeficiency virus-2: dementia, myelopathy, and neuropathy in West Africa. J Neurovirol 2011;17:166-175.

27. Chan LG, Kandiah N, Chua A. HIV-associated neurocognitive disorders (HAND) in a South Asian population - contextual application of the 2007 criteria. BMJ Open 2012;2:e000662.

28. Ku NS, Lee Y, Ahn JY, Song JE, Kim MH, Kim SB, et al. HIV-associated neurocognitive disorder in HIV-infected Koreans: the Korean NeuroAIDS Project. HIV Med 2014;15:470-477.

29. Wang Z, Zheng Y, Liu L, Shen Y, Zhang R, Wang J, et al. High prevalence of HIV-associated neurocognitive disorder in HIV-infected patients with a baseline CD4 count ≤ 350 cells/μL in Shanghai, China. Biosci Trends 2013;7:284-289.

30. Clifford DB, Ances BM. HIV-associated neurocognitive disorder. Lancet Infect Dis 2013;13:976-986.